Belarus Pharmaceuticals & Healthcare Report Q3 2014 - New Market Report

From: Fast Market Research, Inc.
Published: Tue Jun 10 2014

The Belarusian economy is set to suffer a prolonged period of economic instability as a result of a decline in global potash prices and an escalating trade war with Russia. If Russo-Belarusian relations cannot be patched up, state revenues are set to decline considerably, the net exports deficit will widen significantly and real GDP growth will decline. There are downside risks to our 2014 forecast, owing to the threat of further currency depreciation, a collapse in exports and absolute erosion of consumer purchasing power. With the balance of the Belarusian economy once more on knife's edge, Belarus will present little reward for high risk for most pharmaceutical companies in the region.

Full Report Details at

Headline Expenditure Projections

Pharmaceuticals: BYR8,927bn in 2013 (USD1.00bn) to BYR11,039bn (USD1.05mn) in 2014; +23.7% in local currency terms and +4.9% in US dollar terms.

Healthcare: BYR28,966bn (USD3.24bn) in 2013 to BYR35,066bn (USD3.34bn) in 2014; +21.4% in local currency terms and +2.9% in US dollar terms.

Risk/Reward Rating

In our latest Pharmaceutical Risk/Reward Rating (RRR) matrix, Belarus is 17th out of the 20 countries surveyed in the Central and Easter Europe (CEE) region, having considerably improved since the start of the year. However, although its Rewards variables (and in particular its Industry Rewards) are favourable, Belarus will continue to represent a very risky market on account of unresolved issues, such as the lack of patent protection, corruption and political tensions.

Key Trends And Developments

* Belarus's health ministry has proposed introducing uniform margins on drugs in pharmacies, reports Interfax. Drug suppliers will have to follow a price range set in US dollar terms. Health Minister Vasily Zharkov stated that the proposed bill will introduce the concept of a selling price i.e. the price that will be stated by the manufacturer during the state registration of medicines.
* Russia's preferential treatment rules in government...

The Belarus Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belarus Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belarusian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Belarus to test other views - a key input for successful budgeting and strategic business planning in the Belarusian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014
- Jordan Pharmaceuticals & Healthcare Report Q3 2014

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »